摘要
尽管头部和颈部癌症(HNSCC)的治疗取得了不断的发展和重大的进步,它仍然是全球最具破坏性的癌症,每年造成大约350000人死亡。临床和基础研究表明,转录因子NF-κB在HNSCC的持久表达是导致癌症细胞增殖、生存、入侵、转移和该种疾病患者生存率低的根源。NF-κB的激活是实际存在的的,大多数癌变前的发育异常的病变,显示这是该疾病的恶性转化的早期事件。因此,抑制或阻止NF-κB的活动,将导致与肿瘤细胞生长和病灶转移相关的细胞关键过程的下调。 此外,大量证据表明,HNSCC对化疗和辐射抵抗性是治疗失败的主要原因,而NF-κB在此过程中扮演着不可或缺的角色。这表明NF -κB是治疗该疾病的的潜在的靶点。 本文总结NF-κB在 HNSCC发展中的作用,以及使用NF-κB作为靶点开发治疗这种疾病的高效新型治疗方法的潜力。
关键词: NF-κB IκBα
图形摘要
Current Drug Targets
Title:Nuclear Factor Kappa B: A Potential Target to Persecute Head and Neck Cancer
Volume: 18 Issue: 2
Author(s): Javadi Monisha, Nand Kishor Roy, Devivasha Bordoloi, Amit Kumar, Ramesh Golla, Jibon Kotoky, Ganesan Padmavathi and Ajaikumar B. Kunnumakkara
Affiliation:
关键词: NF-κB IκBα
摘要: Despite the consistent and significant advancements made in the treatment of head and neck cancer (HNSCC), it remains one of the most devastating cancers globally killing approximately 350,000 people every year. Both clinical and basic research revealed that the transcription factor NF-κB, is constitutively expressed in HNSCC and this persistent expression of NF-κB is the root cause of this disease resulting in cancer cell proliferation, survival, invasion, metastases and poor survival of patients. Activation of NF-κB is pragmatic in most of the premalignant dysplastic lesions indicating it as an early episode in malignant transformation of this disease. Therefore, therapies designed to inhibit or block the activity of NF-κB, would result in downregulation of key cellular processes involved in tumor growth and its dissemination to metastatic sites. In addition, substantial evidences have revealed that NF-κB plays an indispensable role in the development of both chemo and radiation resistance in HNSCC which is identified to be a primary cause for the failure of therapies. This shows the potential of targeting NF- κB in developing therapies against this disease. This review summarises the role of NF-κB in the development of HNSCC and the potential of using NF-κB as a target to develop novel highly effective therapies for this disease.
Export Options
About this article
Cite this article as:
Javadi Monisha, Nand Kishor Roy, Devivasha Bordoloi, Amit Kumar, Ramesh Golla, Jibon Kotoky, Ganesan Padmavathi and Ajaikumar B. Kunnumakkara , Nuclear Factor Kappa B: A Potential Target to Persecute Head and Neck Cancer, Current Drug Targets 2017; 18 (2) . https://dx.doi.org/10.2174/1389450117666160201112330
DOI https://dx.doi.org/10.2174/1389450117666160201112330 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
STAT3: A Potential Drug Target for Tumor and Inflammation
Current Topics in Medicinal Chemistry Performance Improvement of Gene Selection Methods using Outlier Modification Rule
Current Bioinformatics New and Emerging Antiresorptive Treatments in Osteoporosis
Current Drug Safety Valproic Acid As Anti-Cancer Drug
Current Pharmaceutical Design Curcumin Nanomedicine: A Road to Cancer Therapeutics
Current Pharmaceutical Design The Changing Face of HIV/AIDS in Treated Patients
Current HIV Research Hypoxia: Targeting the Tumour
Anti-Cancer Agents in Medicinal Chemistry Designing Prodrugs Based on Special Residues of Human Serum Albumin
Current Topics in Medicinal Chemistry COX-2 Selective Inhibitors, Carbonic Anhydrase Inhibition and Anticancer Properties of Sulfonamides Belonging to This Class of Pharmacological Agents
Mini-Reviews in Medicinal Chemistry A Curcumin Analog, GO-Y078, Effectively Inhibits Angiogenesis through Actin Disorganization
Anti-Cancer Agents in Medicinal Chemistry Store-Dependent Ca2+ Entry in Endothelial Progenitor Cells As a Perspective Tool to Enhance Cell-Based Therapy and Adverse Tumour Vascularization
Current Medicinal Chemistry Cholesterol-Rich Nanoemulsions (LDE) for Drug Targeting of Cholesteryl-Succinyl- 5-Fluorouracil Conjugate
Current Nanoscience The Efficacy and Mechanism of Proteasome Inhibitors in Solid Tumor Treatment
Recent Patents on Anti-Cancer Drug Discovery Engineered Liposomes for Drug Delivery and Biomedical Imaging
Recent Patents on Nanomedicine Functional Domains of Aquaporin-1: Keys to Physiology, and Targets for Drug Discovery
Current Pharmaceutical Design MICA Gene and Relevance to Immune Responses in Organ Transplants and Inflammatory, Tumoral and Autoimmune Diseases
Current Immunology Reviews (Discontinued) Monitoring T Cell Responses to Cancer Immunotherapy: Can We Now Identify Biomarkers Predicting Patients Who will be Responders
Current Cancer Therapy Reviews Betulinic Acid as a Potent and Complex Antitumor Phytochemical: A Minireview
Anti-Cancer Agents in Medicinal Chemistry Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery
Current Medicinal Chemistry Inhibition of PI3K/Akt Signaling: An Emerging Paradigm for Targeted Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents